vs
Side-by-side financial comparison of T Stamp Inc (IDAI) and Inhibikase Therapeutics, Inc. (IKT). Click either name above to swap in a different company.
Inhibikase Therapeutics, Inc. is the larger business by last-quarter revenue ($1.0M vs $908.9K, roughly 1.1× T Stamp Inc). T Stamp Inc runs the higher net margin — -279.9% vs -1223.3%, a 943.4% gap on every dollar of revenue.
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel disease-modifying therapies for neurodegenerative disorders including Parkinson's disease. It advances pipeline candidates through preclinical and clinical studies to address unmet medical needs and improve patient outcomes worldwide.
IDAI vs IKT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $908.9K | $1.0M |
| Net Profit | $-2.5M | $-12.7M |
| Gross Margin | — | — |
| Operating Margin | -224.9% | -1323.3% |
| Net Margin | -279.9% | -1223.3% |
| Revenue YoY | -39.3% | — |
| Net Profit YoY | 57.7% | -5.0% |
| EPS (diluted) | $-0.37 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $908.9K | $1.0M | ||
| Q3 25 | $872.5K | $0 | ||
| Q2 25 | $812.7K | $0 | ||
| Q1 25 | $545.5K | $0 | ||
| Q4 24 | $1.5M | $0 | ||
| Q3 24 | $511.1K | $0 | ||
| Q2 24 | $500.4K | $0 | ||
| Q1 24 | $573.7K | $0 |
| Q4 25 | $-2.5M | $-12.7M | ||
| Q3 25 | $-1.9M | $-11.9M | ||
| Q2 25 | $-1.7M | $-9.9M | ||
| Q1 25 | $-2.2M | $-13.7M | ||
| Q4 24 | $-6.0M | $-12.1M | ||
| Q3 24 | $-1.3M | $-5.8M | ||
| Q2 24 | $-2.6M | $-5.0M | ||
| Q1 24 | $-2.7M | $-4.6M |
| Q4 25 | -224.9% | -1323.3% | ||
| Q3 25 | -203.0% | — | ||
| Q2 25 | -207.0% | — | ||
| Q1 25 | -396.5% | — | ||
| Q4 24 | -81.2% | — | ||
| Q3 24 | -523.7% | — | ||
| Q2 24 | -524.7% | — | ||
| Q1 24 | -496.7% | — |
| Q4 25 | -279.9% | -1223.3% | ||
| Q3 25 | -219.1% | — | ||
| Q2 25 | -210.7% | — | ||
| Q1 25 | -395.5% | — | ||
| Q4 24 | -401.5% | — | ||
| Q3 24 | -245.7% | — | ||
| Q2 24 | -519.3% | — | ||
| Q1 24 | -466.9% | — |
| Q4 25 | $-0.37 | $-0.10 | ||
| Q3 25 | $-0.72 | $-0.13 | ||
| Q2 25 | $-0.69 | $-0.11 | ||
| Q1 25 | $-0.89 | $-0.15 | ||
| Q4 24 | $-3.14 | $0.88 | ||
| Q3 24 | $-1.06 | $-0.65 | ||
| Q2 24 | $-3.19 | $-0.66 | ||
| Q1 24 | $-3.97 | $-0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.0M | $218.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.7M | $172.9M |
| Total Assets | $11.2M | $181.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.0M | $218.3M | ||
| Q3 25 | $5.4M | $39.1M | ||
| Q2 25 | $292.1K | $9.9M | ||
| Q1 25 | $1.1M | $19.7M | ||
| Q4 24 | $2.8M | $138.6M | ||
| Q3 24 | $598.0K | $2.3M | ||
| Q2 24 | $659.5K | $4.9M | ||
| Q1 24 | $816.7K | $7.4M |
| Q4 25 | $8.7M | $172.9M | ||
| Q3 25 | $6.1M | $72.9M | ||
| Q2 25 | $2.4M | $80.1M | ||
| Q1 25 | $4.1M | $85.7M | ||
| Q4 24 | $3.0M | $94.9M | ||
| Q3 24 | $5.4M | $-530.6K | ||
| Q2 24 | $750.4K | $5.1M | ||
| Q1 24 | $1.4M | $6.8M |
| Q4 25 | $11.2M | $181.2M | ||
| Q3 25 | $11.2M | $79.6M | ||
| Q2 25 | $5.7M | $88.9M | ||
| Q1 25 | $6.6M | $94.3M | ||
| Q4 24 | $8.6M | $98.6M | ||
| Q3 24 | $10.6M | $4.4M | ||
| Q2 24 | $5.2M | $8.8M | ||
| Q1 24 | $5.6M | $11.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-7.5M |
| Free Cash FlowOCF − Capex | $2.0M | — |
| FCF MarginFCF / Revenue | 215.4% | — |
| Capex IntensityCapex / Revenue | 0.8% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-7.5M | ||
| Q3 25 | $-4.0M | $-10.6M | ||
| Q2 25 | $-2.1M | $-5.6M | ||
| Q1 25 | $-1.5M | $-4.1M | ||
| Q4 24 | $-2.7M | $-5.3M | ||
| Q3 24 | $-2.4M | $-4.9M | ||
| Q2 24 | $-1.6M | $-5.1M | ||
| Q1 24 | $-2.2M | $-3.9M |
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-4.0M | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-1.6M | $-4.1M | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | 215.4% | — | ||
| Q3 25 | -459.6% | — | ||
| Q2 25 | -258.6% | — | ||
| Q1 25 | -289.2% | — | ||
| Q4 24 | -182.9% | — | ||
| Q3 24 | -475.4% | — | ||
| Q2 24 | -320.9% | — | ||
| Q1 24 | -376.6% | — |
| Q4 25 | 0.8% | 0.0% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 0.5% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
